Back to Search
Start Over
Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents
- Source :
- Clinical Cancer Research, 17(8), 2110-2119
- Publication Year :
- 2011
- Publisher :
- American Association for Cancer Research (AACR), 2011.
-
Abstract
- Purpose: High-grade osteosarcoma is a malignant primary bone tumor with a peak incidence in adolescence. Overall survival (OS) of patients with resectable metastatic disease is approximately 20%. The exact mechanisms of development of metastases in osteosarcoma remain unclear. Most studies focus on tumor cells, but it is increasingly evident that stroma plays an important role in tumorigenesis and metastasis. We investigated the development of metastasis by studying tumor cells and their stromal context. Experimental Design: To identify gene signatures playing a role in metastasis, we carried out genome-wide gene expression profiling on prechemotherapy biopsies of patients who did (n = 34) and patients who did not (n = 19) develop metastases within 5 years. Immunohistochemistry (IHC) was performed on pretreatment biopsies from 2 additional cohorts (n = 63 and n = 16) and corresponding postchemotherapy resections and metastases. Results: A total of 118/132 differentially expressed genes were upregulated in patients without metastases. Remarkably, almost half of these upregulated genes had immunological functions, particularly related to macrophages. Macrophage-associated genes were expressed by infiltrating cells and not by osteosarcoma cells. Tumor-associated macrophages (TAM) were quantified with IHC and associated with significantly better overall survival (OS) in the additional patient cohorts. Osteosarcoma samples contained both M1- (CD14/HLA-DRα positive) and M2-type TAMs (CD14/CD163 positive and association with angiogenesis). Conclusions: In contrast to most other tumor types, TAMs are associated with reduced metastasis and improved survival in high-grade osteosarcoma. This study provides a biological rationale for the adjuvant treatment of high-grade osteosarcoma patients with macrophage activating agents, such as muramyl tripeptide. Clin Cancer Res; 17(8); 2110–9. ©2011 AACR.
- Subjects :
- Cancer Research
Pathology
medicine.medical_specialty
Time Factors
Angiogenesis
Tumor Infiltrating Macrophages
Bone Neoplasms
Metastasis
Cohort Studies
Metastasis Suppression
Cell Line, Tumor
medicine
Humans
Neoplasm Metastasis
Oligonucleotide Array Sequence Analysis
Osteosarcoma
Reverse Transcriptase Polymerase Chain Reaction
business.industry
Gene Expression Profiling
Macrophages
Cancer
Prognosis
medicine.disease
Immunohistochemistry
Gene Expression Regulation, Neoplastic
Oncology
Cancer research
muramyl tripeptide prognostic-factors gene-expression molecular characterization neoadjuvant chemotherapy breast-cancer survival cells polarization progression
Sarcoma
business
CD163
Subjects
Details
- ISSN :
- 15573265 and 10780432
- Volume :
- 17
- Database :
- OpenAIRE
- Journal :
- Clinical Cancer Research
- Accession number :
- edsair.doi.dedup.....4f0c407184305151be00189c70851fdb
- Full Text :
- https://doi.org/10.1158/1078-0432.ccr-10-2047